8-K: Phio Pharma Advances PH-762, Boosts Cash in Q2 2025

Phio Pharmaceuticals reported Q2 2025 financial results, highlighted by clinical progress for its lead cancer therapeutic PH-762 and a significant increase in cash reserves.

Summary

• Reported financial results for the quarter ended June 30, 2025.
• PH-762 Phase 1b clinical trial is enrolling its 5th and final cohort, with 15 patients treated across four cohorts.
• No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects observed for PH-762.
• Pathologic responses in 13 cSCC patients include 5 complete responses (100% clearance), 1 near complete response (>90% clearance), 1 partial response (>50% clearance), and 6 non-responses (<50% clearance).
• A Merkel cell carcinoma patient showed a pathological partial response (>50% clearance), while a melanoma patient was a non-responder (<50% clearance).
• Cash and cash equivalents increased to $10.8 million at June 30, 2025, from $5.4 million at December 31, 2024.
• Net loss for Q2 2025 was $2.2 million, compared to $1.8 million for Q2 2024.
• Raised approximately $2.2 million after expenses through warrant inducement agreements in July 2025.

Sentiment

Score: 7

Explanation: The company reported strong clinical progress for its lead candidate PH-762 with positive safety and initial efficacy signals, particularly in cSCC. The significant increase in cash position and successful capital raise provide a stronger financial foundation. While net loss increased, the per-share loss improved, and the company is advancing its clinical program, which are positive indicators for a clinical-stage biotech.

Positives

• Cash and cash equivalents significantly increased to $10.8 million at June 30, 2025, from $5.4 million at December 31, 2024.
• Successfully completed a capital raise in July 2025, generating approximately $2.2 million after expenses.
• PH-762 demonstrated a favorable safety profile with no dose-limiting toxicities or clinically relevant adverse effects in the Phase 1b trial.
• Observed promising pathologic responses for PH-762 in cutaneous squamous cell carcinoma (cSCC) patients, including 5 complete responses (100% clearance) out of 13 patients.
• Advanced the PH-762 Phase 1b trial to its 5th and final cohort enrollment.
• Secured a U.S. manufacturing agreement for cGMP production of PH-762, supporting future development.
• Presented positive interim clinical data at multiple scientific conferences (SID, ITOC 11, ASCO).
• Net loss per share significantly improved to $(0.45) in Q2 2025 from $(3.62) in Q2 2024, despite an increased net loss, indicating effective capital management relative to share count.

Negatives

• Net loss increased to $2.2 million for Q2 2025 from $1.8 million for the same period in 2024.
• Research and development expenses increased to $1.1 million in Q2 2025 from $0.9 million in Q2 2024, driven by higher CRO costs and personnel expenses.
• General and administrative expenses increased to $1.2 million in Q2 2025 from $1.0 million in Q2 2024, primarily due to higher salary-related costs.
• Six out of 13 cSCC patients in the Phase 1b trial showed a pathologic non-response (<50% clearance).
• The metastatic melanoma patient in the Phase 1b trial was a non-responder (<50% clearance).

Risks

• Uncertainty regarding results from preclinical and clinical activities.
• Challenges in executing business strategies.
• Uncertainty regarding the timing or likelihood of regulatory filings and approvals.
• Potential difficulties in manufacturing and supplying product candidates for clinical activities and commercial use.
• Ability to establish and maintain intellectual property rights covering the technology platform.
• Ability to obtain future financing.
• Impact of market and other general economic conditions.
• Risks identified in the company's Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

The company anticipates completing the treatment phase of its ongoing Phase 1b clinical trial for PH-762. It also expects its INTASYL siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells and views PH-762 as a potential non-surgical alternative for skin cancer.

Management Comments

• PHIO is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL siRNA gene silencing technology to eliminate cancer.
• PH-762 has been well tolerated in all enrolled patients in each escalating dose cohort.
• No patients exhibited clinical progression of disease during the treatment phase of this trial.
• PH-762 is a potential non-surgical treatment for skin cancers.

Industry Context

Phio Pharmaceuticals operates in the highly competitive and capital-intensive immuno-oncology and gene silencing biotechnology sector. The advancement of its lead candidate PH-762 into the final cohort of its Phase 1b trial, coupled with positive safety and initial efficacy signals in various skin cancers, positions the company to potentially address unmet needs in non-surgical cancer treatments. The focus on INTASYL siRNA technology aligns with broader industry trends exploring novel modalities for targeted cancer therapy, though significant clinical and regulatory hurdles remain common for companies at this stage.

Comparison to Industry Standards

• The reported complete response rate of 5 out of 13 (38.5%) cSCC patients and a partial response in a Merkel cell carcinoma patient for an intratumoral siRNA therapeutic in a Phase 1b setting is encouraging, particularly given the safety profile.
• While direct comparisons are challenging without larger, controlled trials, these early results suggest PH-762 could potentially offer a differentiated approach compared to existing surgical or systemic therapies for advanced skin cancers.
• Traditional treatments for advanced cSCC often involve surgery, radiation, or systemic therapies like PD-1 inhibitors (e.g., Libtayo by Regeneron/Sanofi, Keytruda by Merck), which have varying response rates and side effect profiles.
• The non-response in the melanoma patient, however, highlights the heterogeneous nature of cancer and the need for further investigation into specific indications and patient populations.
• The company's progress to the final cohort of Phase 1b is a standard milestone for clinical-stage biotechs.

Stakeholder Impact

• Shareholders: Positive impact from increased cash runway and clinical progress, but dilution from warrant exercises. Potential for future value creation if PH-762 continues to show positive results.
• Patients: Potential for a new, non-surgical treatment option for various skin cancers, particularly if PH-762 proves effective and safe in larger trials.
• Employees: Continued employment and potential growth opportunities as clinical programs advance.
• Suppliers/Partners: Strengthened relationships with manufacturing partners and CROs due to ongoing development and increased activity.

Next Steps

• Enroll patients in the 5th and final cohort of the Phase 1b clinical trial for PH-762.
• Continue analytical and process development, and cGMP manufacture of PH-762 with the U.S. manufacturing company.
• Further clinical development of PH-762, potentially leading to later-stage trials.
• Potential future regulatory filings and approvals for PH-762.

Key Dates

Recommendation

While the clinical progress for PH-762, particularly the positive safety profile and early efficacy signals in cSCC, is encouraging for a clinical-stage biotech, and the cash position has significantly improved, the company remains in early-stage development. The increased net loss, even with improved EPS due to dilution, indicates ongoing cash burn. The non-response in some cSCC patients and the melanoma patient also highlight the inherent risks. The stock is a 'hold' for investors who are comfortable with the high-risk, high-reward nature of clinical-stage biopharmaceuticals and believe in the long-term potential of the INTASYL platform, but it's too early for a 'buy' given the significant hurdles ahead, and not a 'sell' given the positive developments.

Keywords

Phio Pharmaceuticals, PHIO, INTASYL, siRNA, gene silencing, immuno-oncology, cancer therapeutics, PH-762, cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma, clinical trial, Phase 1b, biotechnology, drug development, financial results, Q2 2025, cash position, capital raise